PBMs push back: Drug middlemen take aim at the FTC
BY Blinn E Combs, Esq. and Michael Alexander, Esq., Brown & Fortunato, P.C. As we reported here in August, the Federal Trade Commission (“FTC”) recently released a draft report broadly accusing Pharmacy Benefit Managers or “PBMs”—the middlemen who negotiate prescription drug prices—of engaging in an array of tactics to drive up prescription drug costs. The FTC’s long-expected suit was filed on September 20. The complaint accuses PBMs of “manipulation of drug price competition for...